Kurs & Likviditet
|2022-11-29||Extra Bolagsstämma 2022|
|2022-05-19||Ordinarie utdelning ALZCUR 0.00 SEK|
|2021-05-18||Ordinarie utdelning ALZCUR 0.00 SEK|
|2020-05-22||Ordinarie utdelning ALZCUR 0.00 SEK|
|2019-05-23||Ordinarie utdelning ALZCUR 0.00 SEK|
|Lista||First North Stockholm|
|Industri||Läkemedel & Handel|
AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of small molecule candidate drugs for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that the company’s presentation at the scientific conference ISMND 2022 is now available in its entirety on the company website. The abstract demonstrates new preclinical data with the company’s leading drug candidate NeuroRestore ACD856, which is being developed with a focus on Alzheimer's disease.
The abstract, titled The Trk-PAM ACD856 improves mitochondrial function and increase BDNF levels in primary cortical neurons, was presented by Pontus Forsell, Head of Research and Discovery på AlzeCure, and includes new preclinical data on ACD856, the lead drug candidate in the NeuroRestore project.
Data from the study show that ACD856 has a potential neuroprotective effect in a cellular model of nerve injury. These protective properties are believed to be mediated by an improved mitochondrial function and a protective effect on the structure of the cell, which has been demonstrated in the presented studies. Furthermore, ACD856 also increases the release of Brain Derived Neurotrophic Factor, BDNF, from the cells, something that is believed to further enhance these positive effects.
ACD856, which is a positive modulator of both NGF/TrkA and BDNF/TrkB mediated signaling, has demonstrated in preclinical studies to improve cognition and memory and is ready for phase 2 clinical studies, where it is being developed primarily for the treatment of Alzheimer's disease.
”These new data demonstrate potential disease-modifying effects of ACD856, in addition to the positive effects we have seen on memory and learning. The neuroprotective properties we see are important, as dysfunction and loss of neurons correlates strongly with impaired function in Alzheimer's patients,” said Pontus Forsell.
”We are very excited about the new results with ACD856, which significantly strengthen the commercial potential of the project. It also opens up possibilities for new indication areas," said Martin Jönsson, CEO of AlzeCure.
The authors of the abstract are Cristina Parrado, Sanja Juric, Märta Dahlström, Pontus Forsell and Johan Sandin, CSO at AlzeCure.
The presentation is available on AlzeCure’s website (https://www.alzecurepharma.se/en/publications).